At this time, Cayston (aztreonam for inhalation solution) is only available as a brand-name product. However, after the first patent for the drug expires in December 2021, generic Cayston may become available. Although aztreonam is sometimes referred to as the "generic name" for Cayston, it is simply the active ingredient and not a generic version of the drug.
Cayston® (aztreonam for inhalation solution) is a prescription antibiotic approved to improve breathing symptoms in people with cystic fibrosis who have the bacteria Pseudomonas aeruginosa in their lungs. P. aeruginosa is a common cause of lung infections in people with cystic fibrosis.
This medication is made by Gilead Sciences, Inc. It is currently protected by patents that prevent any generic Cayston from being manufactured in the United States.
The first patent for Cayston is set to expire in December 2021. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include things such as lawsuits or patents for new Cayston uses. Once the patents expire, there may be several companies that manufacture a generic Cayston drug.
No -- aztreonam is the active ingredient in Cayston, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.